Drugs Made In America Acquisition Corp. (DMAAR) Total Liabilities (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Total Liabilities for 3 consecutive years, with $9.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 26.87% year-over-year to $9.1 million; the trailing twelve-month figure through Jun 2026 stood at $9.1 million (up 26.87% YoY), and the FY2025 full-year result was $7.3 million, up 814.47% from the prior year.
• Total Liabilities grew to $9.1 million in Q2 2026 per DMAAR's latest filing, from $7.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $9.1 million in Q2 2026 and bottomed at $795669.0 in Q4 2024.
• Historically, Total Liabilities has averaged $6.5 million across 3 years, with a median of $7.3 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities soared 814.47% in 2025, then advanced 26.87% in 2026.
• Over 3 years, Total Liabilities stood at $795669.0 in 2024, then jumped by 814.47% to $7.3 million in 2025, then increased by 25.57% to $9.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $9.1 million, $7.3 million, and $7.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.